# Vericiguat

Drug · id `cardio:vericiguat` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Verquvo

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Vericiguat, sold as Verquvo, is a soluble guanylate cyclase stimulator, a medicine taken by mouth. The US label read lists one use in adults: to reduce the risk of cardiovascular death and hospitalization for heart failure after a hospitalization for heart failure or the need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction below 45%. The label carries a boxed warning for embryo-fetal toxicity, which concerns the unborn child and is recorded separately.

## Technical summary

RxNorm ingredient 2475830; UNII LV66ADM269. MeSH has no descriptor for vericiguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator. The record is filed under the class page for soluble guanylate cyclase stimulators on that evidence. The label read is the Merck Sharp & Dohme LLC label for Verquvo, application NDA214377, effective 2026-01-21 in openFDA. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the title and one sentence of the boxed warning, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Verquvo carries a boxed warning titled embryo-fetal toxicity. It says the medicine may cause fetal harm.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T17:27:14Z. Source state: Current. Version fingerprint: efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb.
     How it applies: Label passage quoted in the research quote table (LB-07).
  2. Supports: openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph. Retrieved 2026-11-18T17:27:14Z. Source state: Current. Version fingerprint: efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb.
     How it applies: Label passage quoted in the research quote table (LB-08).
  3. Background: openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:14Z. Source state: Current. Version fingerprint: efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb.
     How it applies: Effective date of the label text read, 20260121.

## Context: Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo

Recipient: Adult; Population: Adults with symptomatic chronic heart failure and an ejection fraction less than 45%, following a hospitalization for heart failure or the need for outpatient intravenous diuretics, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Verquvo (vericiguat tablets, Merck Sharp & Dohme LLC, application NDA214377; the version dated 2026-01-21 in openFDA) describes vericiguat as a soluble guanylate cyclase stimulator. It lists reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with symptomatic chronic heart failure and an ejection fraction less than 45%, following a hospitalization for heart failure or the need for outpatient intravenous diuretics, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning is in a separate claim about the fetus. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, second sentence. Retrieved 2026-11-18T17:27:14Z. Source state: Current. Version fingerprint: efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T17:27:14Z. Source state: Current. Version fingerprint: efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-06).
  3. Background: openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning (Regulator, edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:14Z. Source state: Current. Version fingerprint: efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb.
     How it applies: Effective date of the label text read, 20260121.

## Connected pages

- FDA label lists reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45% as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-vericiguat-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- The FDA established pharmacologic class of vericiguat in RxClass is Soluble Guanylate Cyclase Stimulator: Soluble guanylate cyclase stimulators (`cardio:soluble-guanylate-cyclase-stimulators`)

## Provenance

Content hash: c94c5f6dba6a2a04cc230cfb0dc7e3800a84311a848d2060d0b3f04fbf69fab8
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
